Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328879 | 0.94 | ALDH1A1 (0.51) | ALDH1A1HSD17B10TDP1PRKAB2PRKAG1 | |
| SCHEMBL24328601 | 0.94 | ALDH1A1 (0.51) | ALDH1A1HSD17B10TDP1PRKAB2PRKAG1 | |
| SCHEMBL15201113 | 0.94 | ALDH1A1 (0.51) | ALDH1A1HSD17B10TDP1PRKAB2PRKAG1 | |
| SCHEMBL10922317 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HSD17B10TDP1SMN1; SMN2HTT | |
| SCHEMBL15201436 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HSD17B10TDP1TAAR1CA2 | |
| SCHEMBL26750495 | 0.79 | ALDH1A1 (0.51) | ALDH1A1HSD17B10TDP1ALOX15SMN1; SMN2 | |
| SCHEMBL28325589 | 0.76 | ALDH1A1 (0.56) | ALDH1A1HSD17B10TDP1CA2HPGD | |
| SCHEMBL30715295 | 0.76 | ALDH1A1 (0.56) | ALDH1A1HSD17B10TDP1SMN1; SMN2HPGD | |
| SCHEMBL2919434 | 0.76 | ALDH1A1 (0.56) | ALDH1A1HSD17B10TDP1SMN1; SMN2HPGD | |
| SCHEMBL1012653 | 0.76 | CHRNB4 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000018-B2 | Thiazolidin-4-one-derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20150051270-A1 | Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease | UNIV NOTTINGHAM (GB) | 2015-02-19 | — | — | US | disclosed |
| EP-2814818-A1 | NOVEL CYCLIC PHENOXY COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE | The University Of Nottingham (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-RE45174-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20130310432-A1 | NOVEL THIAZOLIDIN-4-ONE-DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8524752-B2 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-03 | — | — | US | disclosed |
| WO-2013121209-A1 | NOVEL CYCLIC PHENOXY COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2013-08-22 | — | — | WO | disclosed |
| US-20120302612-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | disclosed |
| US-RE43833-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-RE43728-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-09 | — | — | US | disclosed |
| US-7875726-B2 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-25 | — | — | US | disclosed |
| EP-1689726-B1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-7626037-B2 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-01 | — | — | US | disclosed |
| US-20090275625-A1 | NOVEL THIAZOLIDIN 4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080280962-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-11-13 | — | — | US | disclosed |
| US-7435828-B2 | immunosuppressive agents; low dosages; 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20080146629-A1 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS, LTD. | 2007-04-12 | — | — | US | disclosed |
| EP-1689726-A1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054215-A1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310432-A1 | NOVEL THIAZOLIDIN-4-ONE-DERIVATIVES | TLR4, IRF3, IL4 | ALDH1A1 783/4885HSD17B10 1726/4885TDP1 3331/4885 |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | TLR4, IL4, IRF3 | ALDH1A1 671/4885HSD17B10 1325/4885TDP1 3301/4885 |
| US-20090275625-A1 | NOVEL THIAZOLIDIN 4-ONE DERIVATIVES | TLR4, IRF3, TLR1 | ALDH1A1 835/4885HSD17B10 1706/4885TDP1 3348/4885 |
| US-20080146629-A1 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ICOS, IL2, IKZF3 | ALDH1A1 755/4885HSD17B10 2707/4885TDP1 3727/4885 |
| US-20120302612-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | TLR4, IL4, IRF3 | ALDH1A1 671/4885HSD17B10 1325/4885TDP1 3301/4885 |
| US-20080280962-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | TLR4, IL4, IRF3 | ALDH1A1 671/4885HSD17B10 1325/4885TDP1 3301/4885 |
| US-20150051270-A1 | Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease | OXER1, NPR1, RER1 | ALDH1A1 1182/4885HSD17B10 857/4885TDP1 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.